MedTrace Logo

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy

NCT01962233 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-10-14

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in hypoxic ischemic encephalopathy.

Conditions

  • Hypoxic Ischemic Encephalopathy

Interventions

BIOLOGICAL

mesenchymal stem cells

Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect. Intravenous infusion of umbilical cord derived mesenchymal stem cells

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Baoyong Yan, Doctor · The First Hospital of Hebei Medical University

  • Ping Gu, Doctor · The First Hospital of Hebei Medical University

  • Yanyong Wang, Doctor · The First Hospital of Hebei Medical University

  • Lina Zhang, Master · The First Hospital of Hebei Medical University

  • Jun Zhang, Master · The First Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01962233 on ClinicalTrials.gov